The results of a recent clinical trial conducted in hospitals across India found an anti-inflammatory drug used to treat rheumatoid arthritis improves health outcomes in severely ill COVID-19 patients.
Published in The Lancet Respiratory Medicine on March 4, 2021, researchers from the University of Bristol and Medanta Institute of Education and Research in India found evidence supporting the use of Tocilizumab (Actemra) in critically ill patients.
Read More
